Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation Academic Article uri icon

Overview

MeSH Major

  • Anticoagulants
  • Cost-Benefit Analysis
  • Pyrazoles
  • Pyridones
  • Stroke
  • Warfarin

abstract

  • Apixaban appears to be cost-effective relative to warfarin for secondary stroke prevention in patients with AF, assuming that it is introduced at a price similar to that of dabigatran.

publication date

  • October 2, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3525294

Digital Object Identifier (DOI)

  • 10.1212/WNL.0b013e31826d5fe8

PubMed ID

  • 22993279

Additional Document Info

start page

  • 1428

end page

  • 34

volume

  • 79

number

  • 14